SCHEMBL7244706

SCHEMBL7244706

Fc1ccc(CN2CCCCC2Cc2ccccc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
SPHK2 Q9NRA0 1/20 0.49
SPHK1 Q9NYA1 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10462905 0.94 SPHK2 (0.50) SPHK2SPHK1
SCHEMBL27492 0.91
SCHEMBL11470279 0.90
Ammonia Solution, Strong SCHEMBL7288994 0.90
SCHEMBL2997593 0.86
SCHEMBL5530480 0.86
SCHEMBL16225834 0.86 MEN1 (0.55) SPHK2SPHK1
SCHEMBL11480291 0.86 ALDH1A1 (0.54)
SCHEMBL6695674 0.86 OPRD1 (0.47)
SCHEMBL7245970 0.85 LMNA (0.54)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6534525-B1 Method of using 2- substituted piperidine analogs as selectively active antagonist of N-methyl-D-aspartate (NMDA) receptor subtypes for treating conditions such as stroke, cerebral ischemia, central nervous system trauma, WARNER-LAMBERT & COMPANY 2003-03-18 US disclosed
US-6124317-A ACTIVE DRUG TREATING STROKE, CEREBRAL ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA, ANXIETY, CONVULSIONS, AMIOGLYCOSIDE ANTIBIOTICS-INDUCED HEARING LOSS, MIGRAINE HEADACHES, CHRONIC PAIN, GLAUCOMA, CMV RETINITIS, PSYCHOSIS WARNER-LAMBERT COMPANY (US) 2000-09-26 US disclosed
WO-1997023215-A1 2-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE-SELECTIVE NMDA RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1997-07-03 WO disclosed